This risk score identified extramedullary AML and HMA pretreatment as significant clinical variables and mutations in NF1, PTPN11, FLT3, TP53, and SF3B1 as significant molecular markers for OS. This evidence concerns the gene TP53 and acute myeloid leukemia.